ARCHIVES

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

Klausner Reaffirms NCI’s “No. 1 Priority” Is Funding investigator-Initiated Research

September 13, 1996

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

September 29, 2000

Texas Voters Approve $3 Billion In Bonds For Cancer Research.

November 9, 2007

In Brief: Satcher Confirmed For U.S. Surgeon General; Bishop Selected As Chancellor Of UCSF

February 13, 1998

NCI Clinical Trials Enrollment Drops to 17,500

February 21, 2014

NCI To Get $1.469 billion In FY88 Appropriations Bill, An Increase Of $67 Million Over FY 1987

January 1, 1988